Management of bullous pemphigoid: The European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology

British Journal of Dermatology

Volumn 172, Issue 4, 2015, Pages 867-877

  Feliciani, C ^a   Joly, P ^b   Jonkman, M F ^c   Zambruno, G ^d   Zillikens, D ^e   Ioannides, D ^f   Kowalewski, C ^g   Jedlickova, H ^h   Karpati S ⁱ   Marinovic, B ^j   Mimouni, D ^k   Uzun, S ^l   Yayli, S ^m   Hertl, M ⁿ   Borradori, L ^o  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITÉ DE ROUEN   (France)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^e UNIVERSITY OF LÜBECK   (Germany)

^f ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^g MEDICAL UNIVERSITY OF WARSAW   (Poland)

^h MASARYK UNIVERSITY   (Czech Republic)

ⁱ SEMMELWEIS UNIVERSITY   (Hungary)

^j KBC Zagreb   (Croatia)

^k TEL AVIV UNIVERSITY   (Israel)

^l AKDENIZ UNIVERSITY   (Turkey)

^m KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

ⁿ PHILIPPS UNIVERSITY MARBURG   (Germany)

^o UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL PROPIONATE; DERMATOLOGICAL AGENT; CORTICOSTEROID; STEROID;

ARTICLE; BULLOUS PEMPHIGOID; CLINICAL EXAMINATION; DERMATOLOGY; DIET SUPPLEMENTATION; GENERAL CONDITION; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; MAINTENANCE THERAPY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SEROLOGY; SKIN CARE; STEROID THERAPY; SYSTEMIC THERAPY; TOPICAL TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VENEREOLOGY; ANAMNESIS; CONSENSUS; DIAGNOSTIC PROCEDURE; HYDROTHERAPY; INTRADERMAL DRUG ADMINISTRATION; PATIENT CARE; PATIENT EDUCATION; PEMPHIGOID, BULLOUS; PRACTICE GUIDELINE; PROCEDURES; SELF HELP;

ADMINISTRATION, CUTANEOUS; ADRENAL CORTEX HORMONES; CLINICAL LABORATORY TECHNIQUES; CONSENSUS; DERMATOLOGIC AGENTS; DIETARY SUPPLEMENTS; HUMANS; HYDROTHERAPY; MEDICAL HISTORY TAKING; PATIENT CARE TEAM; PATIENT EDUCATION AS TOPIC; PEMPHIGOID, BULLOUS; PHYSICAL EXAMINATION; SELF-HELP GROUPS; STEROIDS;

EID: 84943590639     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13717     Document Type: Article

References (60)

1. Di Zenzo G, Della Torre R, Zambruno G, Borradori L,. Bullous pemphigoid: from the clinic to the bench. Clin Dermatol 2012; 30: 3-16.
2. Schmidt E, Zillikens D,. Pemphigoid diseases. Lancet 2013; 381: 320-32.
3. Venning VA, Taghipour K, Mohd Mustapa MF, et al,. British Association of Dermatologists' guidelines for the management of bullous pemphigoid 2012. Br J Dermatol 2012; 167: 1200-14.
4. Murrell DF, Daniel BS, Joly P, et al,. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol 2012; 66: 479-85.
5. Bastuji-Garin S, Joly P, Picard-Dahan C, et al,. Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol 1996; 132: 272-6.
6. Lloyd-Lavery A, Chi CC, Wojnarowska F, et al,. The associations between bullous pemphigoid and drug use: a U.K. case-control study. JAMA Dermatol 2013; 149: 58-62.
7. Della Torre R, Combescure C, Cortés B, et al,. Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort. Br J Dermatol 2012; 167: 1111-17.
8. Joly P, Baricault S, Sparsa A, et al,. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol 2012; 132: 1998-2004.
9. Pohla-Gubo G, Hintner H,. Direct and indirect immunofluorescence for the diagnosis of bullous autoimmune diseases. Dermatol Clin 2011; 29: 365-72.
10. Joly P, Courville P, Lok C, et al,. Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient sera. Dermatology 2004; 208: 16-20.
11. Kelly SE, Wojnarowska F,. The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid. Br J Dermatol 1988; 118: 31-40.
12. Zillikens D, Mascaro JM, Rose PA, et al,. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997; 109: 679-83.
13. Di Zenzo G, Thoma-Uszynski S, Fontao L, et al,. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol 2008; 128: 415-26.
14. Fairley JA, Bream M, Fullenkamp C, et al,. Missing the target: characterization of bullous pemphigoid patients who are negative using the BP180 enzyme-linked immunosorbant assay. J Am Acad Dermatol 2013; 68: 395-403.
15. Machado-Pinto J, McCalmont TH, Golitz LE,. Eosinophilic and neutrophilic spongiosis: clues to the diagnosis of immunobullous diseases and other inflammatory disorders. Semin Cutan Med Surg 1996; 15: 308-16.
16. Vodegel RM, de Jong MCJM, Meijer HJ, et al,. Enhanced diagnostic immunofluorescence using biopsies transported in saline. BMC Dermatol 2004; 4: 10.
17. Terra JB, Meijer JM, Jonkman MF, Diercks GFH,. The n- vs. u-serration is a learnable criterion to differentiate pemphigoid from epidermolysis bullosa acquisita in direct immunofluorescence serration pattern analysis. Br J Dermatol 2013; 169: 100-5.
18. Gammon WR, Kowalewski C, Chorzelski TP, et al,. Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. J Am Acad Dermatol 1990; 22: 664-70.
19. Magro CM, Dyrsen ME,. The use of C3d and C4d immunohistochemistry on formalin-fixed tissue as a diagnostic adjunct in the assessment of inflammatory skin disease. J Am Acad Dermatol 2008; 59: 822.
20. Chan YC, Sun YJ, Ng PP, Tan SH,. Comparison of immunofluorescence microscopy, immunoblotting and enzyme-linked immunosorbent assay methods in the laboratory diagnosis of bullous pemphigoid. Clin Exp Dermatol 2003; 28: 651-6.
21. Roussel A, Benichou J, Randriamanantany ZA, et al,. Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. Arch Dermatol 2011; 147: 293-8.
22. Labib RS, Anhalt GJ, Patel HP, et al,. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol 1986; 136: 1231-5.
23. De Jong MC, Bruins S, Heeres K, et al,. Bullous pemphigoid and epidermolysis bullosa acquisita. Differentiation by fluorescence overlay antigen mapping. Arch Dermatol 1996; 132: 151-7.
24. Wozniak K, Kazama T, Kowalewski C,. A practical technique for differentiation of subepidermal bullous diseases. Arch Dermatol 2003; 139: 1007-11.
25. van Beek N, Rentzsch K, Probst C, et al,. Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet J Rare Dis 2012; 7: 49.
26. Bédane C, Prost C, Bernard P, et al,. Cicatricial pemphigoid antigen differs from bullous pemphigoid antigen by its exclusive extracellular localization: a study by indirect immunoelectron microscopy. J Invest Dermatol 1991; 97: 3-9.
27. Joly P, Benichou J, Lok C, et al,. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol 2005; 141: 691-8.
28. Cortes B, Marazza G, Naldi L, et al,. Mortality of bullous pemphigoid in Switzerland: a prospective study. Br J Dermatol 2011; 165: 368-74.
29. Joly P, Roujeau JC, Benichou J, et al,. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346: 321-7.
30. Joly P, Roujeau JC, Benichou J, et al,. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009; 129: 1681-7.
31. Kirtschig G, Middleton P, Bennett C, et al,. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010; 6: 10.
32. Daniel BS, Borradori L, Hall RP 3rd, Murrell DF,. Evidence-based management of bullous pemphigoid. Dermatol Clin 2011; 29: 613-20.
33. Singh S,. Evidence-based treatments for pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid: a systematic review. Indian J Dermatol Venereol Leprol 2011; 77: 456-69.
34. Roujeau JC, Guillaume JC, Morel P, et al,. Plasma exchange in bullous pemphigoid. Lancet 1984; 2: 486-8.
35. Fivenson DP, Breneman DL, Rosen GB, et al,. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994; 130: 753-8.
36. Guillaume JC, Vaillant L, Bernard P, et al,. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993; 129: 49-53.
37. Beissert S, Werfel T, Frieling U, et al,. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 2007; 143: 1536-42.
38. Bystryn JC,. Comparative effectiveness of azathioprine or mycophenolate mofetil as an adjuvant for the treatment of bullous pemphigoid. Arch Dermatol 2008; 144: 946.
39. Du-Thanh A, Merlet S, Maillard H, et al,. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol 2011; 165: 1337-43.
40. Bouscarat F, Chosidow O, Picard-Dahan C, et al,. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol 1996; 34: 683-4.
41. Chave TA, Mortimer NJ, Shah DS, Hutchinson PE,. Chlorambucil as a steroid-sparing agent in bullous pemphigoid. Br J Dermatol 2004; 151: 1107-8.
42. Barthélémy H, Thivolet J, Cambazard F, et al,. Cyclosporin in the treatment of bullous pemphigoid: preliminary study. Ann Dermatol Venereol 1986; 113: 309-13.
43. Gaitanis G, Alexis I, Pelidou SH, et al,. High-dose intravenous immunoglobulin in the treatment of adult patients with bullous pemphigoid. Eur J Dermatol 2012; 22: 363-9.
44. Müller PA, Bröcker EB, Klinker E, et al,. Adjuvant treatment of recalcitrant bullous pemphigoid with immunoadsorption. Dermatology 2012; 224: 224-7.
45. Meyersburg D, Schmidt E, Kasperkiewicz M, Zillikens D,. Immunoadsorption in dermatology. Ther Apher Dial 2012; 16: 311-20.
46. Schmidt E, Seitz CS, Benoit S, et al,. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007; 156: 352-6.
47. Hall RP 3rd, Streilein RD, Hannah DL, et al,. Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. J Invest Dermatol 2013; 133: 2786-8.
48. Fairley JA, Baum CL, Brandt DS, et al,. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 2009; 123: 704-5.
49. Gual A, Iranzo P, Mascarõ JM Jr,. Treatment of bullous pemphigoid with low-dose oral cyclophosphamide: a case series of 20 patients. J Eur Acad Dermatol Venereol 2014; 28: 814-18.
50. Le Roux-Villet C, Prost-Squarcioni C, Oro S, et al,. Role of the nurse in care of bullous pemphigoid. Rev Infirm 2010; 160: 38-40.
51. BC Cancer Agency. Immunization guidelines. Available at: http://www.bccancer.bc.ca/NR/rdonlyres/8B9A8033-61A8-4862-B113-96916C59C04C/12801/ImmunizationGuidelines.pdf (last accessed 21 January 2015).
52. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00023141.htm (last accessed 21 January 2015).
53. Grossmann JM, Gordon R, Ranganath VK, et al,. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62: 1515-26.
54. Fichel F, Barbe C, Joly P, et al,. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study. JAMA Dermatol 2014; 150: 25-33.
55. Bernard P, Reguiai Z, Tancrède-Bohin E, et al,. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol 2009; 145: 537-42.
56. Bernard P, Bedane C, Prost C, et al,. [ Bullous pemphigoid Guidelines for the diagnosis and treatment. Centres de Référence des Maladies Bulleuses Auto-immunes. Société Française de Dermatologie ]. Ann Dermatol Venereol 2011; 138: 247-51 (in French).
57. European Dermatology Forum. SOP for creation of European Dermatology Guidelines. Available at: http://www.turkderm.org.tr/turkdermData/Uploads/files/Guidelines%20-SOP.pdf (last accessed 22 January 2015).
58. AGREE. Practice guidelines. Available at: http://www.agreetrust.org/resource-centre/practice-guidelines/ (last accessed 22 January 2015).
59. Haute Autorité de Santé. Guide d'analyse de la littérature et gradation des recommandations. Available at: http://www.has-sante.fr/portail/jcms/c-434715/fr/guidedanalyze (last accessed 22 January 2015).
60. AWMF. Guidelines: Klassifikation S2-Leitlinen. Available at: http://www.awmf.org/en/clinical-practice-guidelines/awmf-guidance/cpg-development/awmf-regelwerk-01-planung-und-organisation/po-stufenklassifikation/klassifikation-s2e-und-s2k.html (last accessed 22 January 2015).